BG93111A - Кит за получаване на енанциомерна форма на диагностично средство за бъбречната функция технециев-99м-меркаптоацетил- триглицин (горе 99м тс-маг-3) и метод за получаването му - Google Patents
Кит за получаване на енанциомерна форма на диагностично средство за бъбречната функция технециев-99м-меркаптоацетил- триглицин (горе 99м тс-маг-3) и метод за получаването муInfo
- Publication number
- BG93111A BG93111A BG093111A BG9311190A BG93111A BG 93111 A BG93111 A BG 93111A BG 093111 A BG093111 A BG 093111A BG 9311190 A BG9311190 A BG 9311190A BG 93111 A BG93111 A BG 93111A
- Authority
- BG
- Bulgaria
- Prior art keywords
- mag
- obtaining
- kit
- coligand
- hydroxide
- Prior art date
Links
- 230000003907 kidney function Effects 0.000 title abstract 2
- 108010055917 Technetium Tc 99m Mertiatide Proteins 0.000 title 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 3
- RXACEEPNTRHYBQ-UHFFFAOYSA-N 2-[[2-[[2-[(2-sulfanylacetyl)amino]acetyl]amino]acetyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)CNC(=O)CNC(=O)CS RXACEEPNTRHYBQ-UHFFFAOYSA-N 0.000 abstract 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 abstract 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract 2
- 230000003647 oxidation Effects 0.000 abstract 2
- 238000007254 oxidation reaction Methods 0.000 abstract 2
- 230000000087 stabilizing effect Effects 0.000 abstract 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000001476 alcoholic effect Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 235000012208 gluconic acid Nutrition 0.000 abstract 1
- 239000000174 gluconic acid Substances 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 239000008055 phosphate buffer solution Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 235000002906 tartaric acid Nutrition 0.000 abstract 1
- 239000011975 tartaric acid Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Изобретението намира приложение за нуклеарномедицински изследвания на бъбречната функция. Китът съдържа два компонента, напълнени отделно във флакони. Първият компонент се състои от лиофилизирана смес от меркаптоацетилтриглицин (маг-3), стабилизиращ окислителния етап +5 на тс колиганд, редукционно средство и алкален, респ. Алкалоземен, хидроокис в молно съотношение 1 : (50 150) : (0,1 0,5) : (30 80). Вторият компонент представлява стерилен фосфатно-буферен разтвор с киселина в количество, съответстващо на молното съотношение на маг-3 и хидроокиса. В една предпочитана разработка като колиганд се влага сол на винената или на глюконовата киселина, по-специално nа2-тартрат, като редукционно средство се влага sn2сl и като хидроокис nаон. Първият компонент на кита се получава чрез осапунване на бензоил-маг-3 с алкохолат в алкохолен разтвор и смесване на получения лиганд меркаптоацетилтриглицин с намираща се в незащитена форма меркаптогрупа с редукционното средство и със стабилизиращия окислителния етап +5 на тс колиганд при рн, по-високо от 11, в посочените по-горе съотношения. Следват лиофилизиране и напълване на порции във флакони. 5 претенции
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DD33403489A DD288751B5 (de) | 1989-10-30 | 1989-10-30 | Kit (nichtradioaktive Vorstufe) zur Herstellung einer enantiomeren Form des Nierenfunktionsdiagnostikums Technetium-99m-Mercaptoacetyltriglycin 99m Tc-MAG-3 und Verfahren zur Herstellung des Kits |
| DD33403589A DD288752B5 (de) | 1989-10-30 | 1989-10-30 | Verfahren zur Herstellung einer enantiomeren Form des Nierenfunktionsdiagnostikums Technetium-99m-Mercaptoacetyltriglycin 99mTc-MAG-3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG93111A true BG93111A (bg) | 1993-12-24 |
| BG60502B1 BG60502B1 (bg) | 1995-06-30 |
Family
ID=25748305
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG93111A BG60502B1 (bg) | 1989-10-30 | 1990-10-29 | Кит за получаване на енанциомерна форма на диагностично средство за бъбречната функция технециев-99м-меркаптоацетил- триглицин (горе 99м тс-маг-3) иметод за получаването му |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0427360B1 (bg) |
| AT (1) | ATE107173T1 (bg) |
| BG (1) | BG60502B1 (bg) |
| CZ (1) | CZ278025B6 (bg) |
| DE (2) | DE122005000028I2 (bg) |
| HU (1) | HU206774B (bg) |
| SK (1) | SK531690A3 (bg) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2860157B2 (ja) * | 1990-10-31 | 1999-02-24 | 日本メジフィジックス株式会社 | 腎機能測定用の既放射能標識テクネチウムキレート注射剤の製造方法 |
| US5744120A (en) * | 1993-03-30 | 1998-04-28 | The Dupont Merick Pharmaceutical Company | Ternary radiopharmaceutical complexes |
| GB201402132D0 (en) * | 2014-02-07 | 2014-03-26 | South African Nuclear Energy | A method of producing ethylenedicysteine deoxyglucosamine (ECDG) or a salt thereof and its application in a kit |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673562A (en) * | 1983-08-19 | 1987-06-16 | The Children's Medical Center Corporation | Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents |
| US4670545A (en) * | 1984-05-11 | 1987-06-02 | University Patents, Inc. | Chelating agents for technetium-99M |
| US4746505A (en) * | 1985-04-26 | 1988-05-24 | President And Fellows Of Harvard College | Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands |
| ATE106898T1 (de) * | 1987-03-26 | 1994-06-15 | Neorx Corp | Metall-radionuklid-markierte proteine und glykoproteine zur diagnose und therapie. |
-
1990
- 1990-10-23 DE DE200512000028 patent/DE122005000028I2/de active Active
- 1990-10-23 DE DE59006132T patent/DE59006132D1/de not_active Expired - Lifetime
- 1990-10-23 EP EP90250271A patent/EP0427360B1/de not_active Expired - Lifetime
- 1990-10-23 AT AT90250271T patent/ATE107173T1/de not_active IP Right Cessation
- 1990-10-29 BG BG93111A patent/BG60502B1/bg unknown
- 1990-10-30 SK SK5316-90A patent/SK531690A3/sk unknown
- 1990-10-30 HU HU906944A patent/HU206774B/hu unknown
- 1990-10-30 CZ CS905316A patent/CZ278025B6/cs not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUT58920A (en) | 1992-03-30 |
| HU206774B (en) | 1992-12-28 |
| ATE107173T1 (de) | 1994-07-15 |
| EP0427360A3 (de) | 1991-06-05 |
| EP0427360B1 (de) | 1994-06-15 |
| BG60502B1 (bg) | 1995-06-30 |
| CZ531690A3 (en) | 1993-01-13 |
| DE122005000028I1 (de) | 2005-08-04 |
| DE59006132D1 (de) | 1994-07-21 |
| CZ278025B6 (en) | 1993-07-14 |
| SK277878B6 (en) | 1995-06-07 |
| DE122005000028I2 (de) | 2007-08-16 |
| SK531690A3 (en) | 1995-06-07 |
| HU906944D0 (en) | 1991-05-28 |
| EP0427360A2 (de) | 1991-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6440433A (en) | Aqueous liquid composition of thrombin | |
| KR890004718A (ko) | 안정한 인체 단백질의 제조 | |
| NO863916D0 (no) | Farmasoeytiske materialer av den type som gjennomgaar en vaeskegelfase-omdannelse. | |
| NO873589D0 (no) | Blanding som inneholder ldopa. | |
| KR880007456A (ko) | 테크네튬-99m으로 표지된 기관특이성 물질의 제조방법 | |
| KR890015745A (ko) | 수용액으로 존재하는 피록시캄의 제약 조성물 및 그의 제조방법 | |
| ES2073678T3 (es) | Formulaciones radiofarmaceuticas, su metodo de administracion y procedimiento de preparacion. | |
| KR840005342A (ko) | 정맥투여용 수액제의 제조방법 | |
| DK53086A (da) | Fremgangsmaade til fremstilling af skumdannende praeparater | |
| BG93111A (bg) | Кит за получаване на енанциомерна форма на диагностично средство за бъбречната функция технециев-99м-меркаптоацетил- триглицин (горе 99м тс-маг-3) и метод за получаването му | |
| JPS6416724A (en) | Stable and injectable vinca dimer salt solution | |
| Thomas et al. | Indications of spatial relations among structures recognizing amino acids and Na+ at a transport receptor site | |
| CA2016470A1 (en) | Pharmaceutical preparation and method of treatment for liver dysfunction | |
| ATE47518T1 (de) | Injizierbare pharmazeutische zusammenstellungen die bestaendige 5-adenosyl-l-methionin-salze enthalten. | |
| DE3673227D1 (de) | 99mtc(iii)-agenzien zur myokardialen darstellung, in vivo nichtreduzierbar. | |
| EA200000772A1 (ru) | Фармацевтические композиции и способы их приготовления | |
| HUT59610A (en) | Process for producing pharmaceutical compositions for solving blood clot containing t-pa without glycosilyzing | |
| JPS57169425A (en) | Composition and method for preventing adsorption of secretin | |
| KR920700683A (ko) | t-PA의 가용화 | |
| SU799183A1 (ru) | Средство дл скеннировани печени Коиноль | |
| SU1120394A1 (ru) | Способ моделировани атрио-вентрикул рного блока сердца | |
| RU99102608A (ru) | Способ получения радиотерапевтического препарата | |
| SU637063A1 (ru) | Реактив дл определени тироксинсв зывающей способности белков сыворотки крови | |
| SE7613849L (sv) | For injicering ferdigstellda losningar | |
| SU1462871A1 (ru) | Комплексная добавка для низкотемпературных тампонажных растворов |